Skeletal Dysplasia (including OI)

Genomic and Inherited Disorders

01-SKD-27

Gene panel testing for patients affected with a form of skeletal dysplasia. This EQA now includes Osteogenesis Imperfecta.

Overview

The scheme

is designed to assess the entire diagnostic pipeline of a laboratory, including

sample receipt and processing, analytical processing (genotyping), and

reporting (biological and clinical interpretation of the test result) in the

context of a clinical referral, as well as reporting clarity, content and

clerical accuracy.

At a glance

Product Code:

01-SKD-27

Target/Genes:

Gene panel testing of genes associated with Skeletal Dysplasias. The EQA also contains a guaranteed Osteogenesis imperfecta case (variants in COL1A1 and COL1A2).

Technology:

CNV, MLPA, NGS, Panel testing, Whole exome sequencing, Whole genome sequencing

Sample Type:

DNA (in TE Buffer)

Submit Results In:

English, French, German, Italian, Spanish

Accredited:

No

Key Dates

Register by

30/11/2026

Samples ship

Jan-27

Survey Period

January - March 2027 (for exact dates, please see scheme instructions)

Final Results

August 2027

Sample Details

Four mock clinical cases; 3 with matching samples and 1 virtual case will be provided.

Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Testing can be performed using any appropriate panel for genes associated with skeletal dysplasias and osteogensis imperfecta. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.

Collaboration with European Reference Network on Rare Bone Diseases (ERN-BOND) – see website for more information.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

Send your enquiry by submitting the form

Closes in 21 days

From £467.00

Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.

Add to enquiry list
  • Submit results in 5 languages

Questions about this scheme?
Contact our team

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)